Norges Bank Buys $4.9B J&J Stake as Institutions Reach 69.6% Ownership
Banyan Capital acquired 3,853 Johnson & Johnson shares in Q3 worth $714,000. Norges Bank initiated a $4.877 billion Johnson & Johnson position in Q2, while major investors Vanguard, Laurel Wealth and others hold 237 million, 7.42 million and 60.6 million shares respectively, contributing to institutions’ 69.55% J&J ownership.
1. Institutional Investors Increase Exposure
In its latest SEC filing, Banyan Capital Management Inc. initiated a new position in Johnson & Johnson during Q3, purchasing 3,853 shares valued at approximately $714,000, making J&J its 22nd largest holding at 0.3% of total assets. Other significant movements include Norges Bank’s acquisition of a $4.88 billion stake in Q2; Laurel Wealth Advisors’ outsized 15,040.6% increase, boosting its J&J holding to 7.42 million shares valued at $1.13 billion; Vanguard Group’s 1.3% lift to 237.05 million shares ($36.21 billion); Geode Capital’s 2.1% increase to 60.61 million shares ($9.23 billion); and Legal & General’s 6.2% rise to 18.92 million shares ($2.89 billion). Collectively, institutions now own 69.55% of the company’s equity.
2. Regulatory Green Light for AKEEGA Boosts Pharma Outlook
The European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion on AKEEGA (niraparib plus abiraterone) for BRCA1/2-mutant metastatic hormone-sensitive prostate cancer. This endorsement paves the way for a new oncology franchise, potentially adding several hundred million dollars in annual revenue as J&J advances toward full approval and commercial launch, enhancing the mid-term growth trajectory of its pharmaceutical segment.
3. Analyst Upgrades Reflect Consensus Optimism
Multiple brokerages have raised J&J ratings and targets, underscoring broad buy-side confidence. Daiwa Capital Markets maintained an Outperform and increased its target to $237; Morgan Stanley upgraded on a stronger growth outlook referencing fresh annual highs; Scotiabank lifted its target to $265 post-Q4 results; Citigroup raised its target from $232 to $250 with a Buy rating; and Goldman Sachs reiterated Buy at $250. Among 26 analysts tracked by MarketBeat, one recommends Strong Buy, 17 Buy and eight Hold, yielding an average Moderate Buy consensus and a mean price target of $233.05.
4. Q4 Results and Shareholder Returns Reinforce Financial Strength
In Q4, J&J delivered $24.56 billion in revenue (up 9.1% year-over-year) and GAAP EPS of $2.46, matching consensus. Net margin reached 28.46% and return on equity was 33.34%. Management set fiscal 2026 EPS guidance at 11.430–11.630. The board declared a $1.30 quarterly dividend (2.3% yield), payable March 10 to holders of record February 24, representing a 47.06% payout ratio and marking the company’s 61st consecutive year of dividend increases.